Department of Medical Informatics and Biostatistics, Iuliu Haţieganu University of Medicine and Pharmacy, 6 Pasteur street, 400349 Cluj-Napoca, Romania.
Cluj-Napoca County Emergency Hospital, Centre of Diabetes, Nutrition and Metabolic Diseases, 2 Clinicilor street, 400006 Cluj-Napoca, Romania.
Prim Care Diabetes. 2022 Oct;16(5):684-691. doi: 10.1016/j.pcd.2022.07.005. Epub 2022 Jul 30.
To evaluate whether the Norfolk Quality of Life in Diabetic Neuropathy (QOL-DN) questionnaire and the novel Norfolk Mortality Risk Score (NMRS), comprising Norfolk QOL-DN items, can identify 4-year mortality risk in individuals with diabetes.
Of 21,756 adults completing Norfolk QOL-DN in 2012, two groups of surviving and deceased patients were identified in 2016: Group 1, from a county capital and Group 2, from six small cities. NMRS was calculated in Group 1 using the 2012 scores of Norfolk QOL-DN items that discriminate between deceased and surviving participants (p < 0.05) and was subsequently applied to Group 2.
763 participants were included (Group 1: 481 [450 surviving, 31 deceased]; Group 2: 282 [218 surviving, 64 deceased]). Total Norfolk QOL-DN score was significantly higher (worse) in deceased participants than in survivors in both groups (p ≤ 0.008). Optimal cut-off for the 25-item NMRS was 11.5 in Group 1. Individuals in Groups 1 and 2 with NMRS≥ 11.5 in 2012 had a 4-year mortality risk ratio of 4.24 (95 % confidence interval [CI]: 1.65-10.84) and 2.33 (95 % CI: 1.33-4.07), respectively, corresponding to 8 and 16 additional deaths/100 persons/4 years (p = 0.001).
Norfolk QOL-DN and NMRS can identify individuals with diabetes at risk of 4-year mortality.
评估诺福克糖尿病神经病变生活质量问卷（QOL-DN）和包含诺福克 QOL-DN 项目的新型诺福克死亡率风险评分（NMRS）是否可识别糖尿病患者的 4 年死亡风险。
在 2012 年完成诺福克 QOL-DN 的 21756 名成年人中，2016 年确定了两组存活和死亡患者：组 1，来自县城；组 2，来自六个小城市。在组 1 中使用能区分死亡和存活参与者的诺福克 QOL-DN 项目的 2012 评分计算 NMRS（p < 0.05），随后应用于组 2。
共纳入 763 名参与者（组 1：481 名[450 名存活，31 名死亡]；组 2：282 名[218 名存活，64 名死亡]）。两组中，死亡参与者的总诺福克 QOL-DN 评分均显著高于（更差）存活参与者（p <= 0.008）。组 1 中 25 项 NMRS 的最佳截断值为 11.5。2012 年 NMRS >= 11.5 的组 1 和组 2 个体的 4 年死亡率风险比分别为 4.24（95%置信区间[CI]：1.65-10.84）和 2.33（95% CI：1.33-4.07），分别对应每 100 人/4 年 8 例和 16 例额外死亡（p = 0.001）。
诺福克 QOL-DN 和 NMRS 可识别有 4 年死亡风险的糖尿病患者。
